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Abstract
Most U.S. adults have voluntary rules prohibiting the use of smoked tobacco products in their 
homes and vehicles. However, the prevalence of similar rules for electronic vapor products (EVPs) 
is uncertain. This study assessed the prevalence and correlates of rules prohibiting EVP use inside 
homes and vehicles. Data from a 2017 Internet-based panel survey of U.S. adults aged ≥18 years 
(n=4,107) were analyzed. For homes and vehicles, prevalence of reporting that EVP use was not 
allowed, partially allowed, fully allowed, or unknown was assessed overall and by covariates. 
Correlates of prohibiting EVP use was assessed by multivariable logistic regression. In homes, 
58.6% of adults did not allow EVP use, 7.7% partially allowed use, 10.1% fully allowed use, and 
23.6% were unsure of the rules. In vehicles, 63.8% of respondents did not allow EVP use, 6.0% 
partially allowed use, 8.9% fully allowed use, and 21.4% were unsure of the rules. Following 
multivariable adjustment, prohibiting EVP use inside homes and vehicles was more likely among 
respondents with higher income and education, and with a child aged <18 years. Users of EVPs 
and other tobacco products, and respondents living with users of EVPs and other tobacco products, 
were less likely to prohibit EVP use in these locations. These findings show that about 6 in 10 U.S. 
adults have rules prohibiting EVP use inside homes and vehicles, but variations exist by 
population subgroups. Voluntary smoke-free rules in homes and vehicles that include EVPs can 
help protect children and non-users from secondhand EVP aerosol exposure.
Keywords
Electronic Nicotine Delivery Systems; Home; Vehicle; Tobacco Smoke Pollution; Secondhand 
Smoke; Smoke-free Policy
INTRODUCTION
The health effects of combustible tobacco product use and secondhand smoke (SHS) 
exposure are well established.1 Over the past several decades, significant progress has 
occurred in the adoption of comprehensive smoke-free policies in indoor public places, 
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including worksites, restaurants, and bars.2 Public indoor smoke-free policies are strongly 
associated with the adoption of voluntary smoke-free rules in private settings such as homes 
and vehicles.3 Accordingly, the prevalence of voluntary smoke-free home (83.7%) and 
vehicle (78.1%) rules has also increased among U.S. adults over time.4
In recent years, the tobacco product landscape has evolved to include a variety of newer 
products, including e-cigarettes and other electronic vapor products (EVPs).5 In contrast to 
combustible tobacco products, EVPs do not produce sidestream emissions. Aerosol is only 
produced during activation of the device, some of which is exhaled into the environment as 
secondhand aerosol (SHA) where nonusers can be exposed.5 Although these products 
generally emit fewer toxicants than combustible tobacco products,5 SHA exposure can 
involuntarily expose nonusers, including children, to harmful and potentially harmful 
constituents such as nicotine, ultrafine particulates and volatile organic compounds, among 
others.5
Few studies have assessed voluntary rules prohibiting EVP use in homes and vehicles.6–8 In 
the U.S., two small, non-nationally representative studies reported that 6% of current 
cigarette smokers,6 and 32% of current and former smokers,7 had rules prohibiting EVP use 
in their home; no current smokers reported having rules against EVP use in their vehicles.6 
To date, only one study has assessed EVP rules in homes among tobacco product users and 
non-users.8 This nationally-representative study, conducted in Great Britain, reported that 
57.5% of adults did not allow EVP use inside their homes, but did not report on rules inside 
vehicles.8
To date, no nationally-representative study has assessed the prevalence of voluntary rules 
regarding EVP use inside U.S. homes, and no national or international study has assessed 
the prevalence of voluntary rules for EVP use in vehicles. To address this knowledge gap, 
this study assessed the current prevalence and socio-demographic correlates of self-reported 
rules prohibiting EVP use inside homes and personal vehicles among U.S. adults.
METHODS
Data Source
Data were from the 2017 Summer Styles survey, an Internet-based survey of adults in the 
U.S. aged ≥18 years conducted by Porter Novelli. Respondents were drawn from 
KnowledgePanel ® (GfK), an online panel utilizing a probability-based sampling design to 
recruit panelists regardless of landline phone or Internet access. In June and July 2017, 4,107 
adult panelists completed this survey (response rate: 74%). This analysis used secondary de-
identified data, and thus, did not require human subject review.
Measures
EVP Rules in Homes—Participants were asked, “Which statement best describes the 
rules about using electronic vapor products inside your home?” Responses included: “It is 
not allowed anywhere or at any time inside my home” (not allowed), “It is allowed in some 
places or at some times inside my home” (partially allowed), “It is allowed anywhere and at 
any time inside my home” (fully allowed), and “Don’t know, Not Sure.”
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EVP Rules in Vehicles—Participants were asked, “Regardless of whether you use them, 
which statement best describes the rules about using electronic vapor products inside 
vehicles that you or your family members who live with you own or lease?” Responses 
included: “It is not allowed anywhere or at any time inside any vehicle” (not allowed),” “It is 
allowed inside certain vehicles or during certain times” (partially allowed), “It is allowed 
anywhere and at any time inside any vehicle” (fully allowed), and “Don’t know, Not Sure.” 
Respondents who answered “My family and I do not lease or own any vehicles,” were 
excluded from the analysis.
Covariates—Tobacco-specific covariates included EVP use (never user, tried but not a 
current user, or current user), cigarette smoking status (never, former, or current smoker), 
and current (past 30-day) use of other tobacco products (cigars, smokeless tobacco, pipe 
tobacco, hookah, or some other product) (non-current user or current user). Other covariates 
included sex, age, race/ethnicity, U.S. region, having a child aged <18 years, educational 
attainment, annual household income, and living with someone who uses EVPs or other 
tobacco products.
Analyses
Prevalence (with 95% confidence interval (CI)) of reporting that EVP use was not allowed, 
partially allowed, or fully allowed inside homes and vehicles was assessed overall and by 
each covariate; a response of “don’t know, not sure” was also assessed. Chi-squared tests 
were used to assess significant differences in EVP rules across covariates (p<0.05).
For multivariable analyses, EVP rules were dichotomized as “not allowed” versus “allowed” 
(partially allowed, fully allowed, or don’t know/not sure). Adjusted prevalence ratios (aPR) 
were calculated using binary logistic regression modeling with predictive margins to assess 
the association between each covariate and reporting that EVP use was not allowed.
Data were weighted to represent the U.S. population using distributions from the U.S. 
Census Bureau’s Current Population Survey. All analyses were performed using SAS-
callable SUDAAN version 11 (RTI International, Research Triangle Park, NC).
RESULTS
Inside homes, 58.6% of adults did not allow EVP use; 7.7% partially allowed, 10.1% fully 
allowed, and 23.6% were unsure of the EVP rules. Never EVP users (63.0%) had a higher 
prevalence of not allowing EVP use at home compared to those who had ever tried EVPs but 
were not current users (38.5%) or current (21.6%) EVP users (p<0.05). The prevalence of 
not allowing EVP use in homes was higher for never cigarette smokers (67.5%) than former 
(57.4%) or current smokers (30.1%; p<0.05) and non-users of other tobacco products 
(59.7%) than current users (43.0%; p<0.05) (Table 1).
Inside vehicles, 63.8% did not allow, 6.0% partially allowed, 8.9% fully allowed, and 21.4% 
did not know or were unsure of the EVP rules. By EVP use status, 68.7% of never users, 
41.3% of those who had ever tried EVPs but were not current users, and 20.6% of current 
EVP users reported not allowing EVP use inside vehicles. The prevalence of not allowing 
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EVP use in vehicles was higher for never cigarette smokers (72.8%) than former (64.4%) or 
current smokers (30.7%; p<0.05) and among non-users of other tobacco products (64.9%) 
than current users (45.8%; p<0.05) (Table 1).
The adjusted likelihood of not allowing EVP use inside homes and vehicles was greater 
among adults with a college degree (home: aPR=1.27, CI=1.11–1.45; vehicle: aPR=1.16, 
CI=1.03–1.31) compared to less than high school; those with a child aged <18 years (home: 
aPR=1.15, CI=1.09–1.22; vehicle: aPR=1.12, CI=1.07–1.18) compared to no child; and 
higher annual household income categories compared to less than $15,000 (Table 2). The 
likelihood of not allowing EVP use was lower among non-Hispanic black respondents 
(home: aPR=0.85, CI=0.76–0.95; vehicle: aPR=0.89, CI=0.82–0.98) than non-Hispanic 
white; and those living with an EVP user (home: aPR=0.68, CI=0.55–0.84; vehicle: 
aPR=0.71, CI=0.59–0.86) or other tobacco product user (home: aPR=0.87, CI=0.80–0.95; 
vehicle: aPR=0.84, CI=0.77–0.91) than not living with respective tobacco product users.
Compared to respective non-users, the adjusted likelihood of not allowing EVP use inside 
homes was lower among current EVP users (aPR=0.66, CI=0.48–0.90), those who had tried 
but were not current EVP users (aPR=0.77, CI=0.68–0.86), and current (aPR=0.73, 
CI=0.64–0.83) and former (aPR=0.92, CI=0.86–0.98) cigarette smokers. Not allowing EVP 
use inside vehicles was less likely among current EVP users (aPR=0.59, CI=0.43–0.81), 
those who had tried but were not current EVP users (aPR=0.78, CI=0.70–0.86), current 
(aPR=0.68, CI=0.60–0.77) and former (aPR=0.92, CI=0.86–0.97) cigarette smokers, and 
current users of other tobacco products (aPR=0.85, CI=0.74–0.97) than respective non-users.
DISCUSSION
In 2017, approximately 6 in 10 adults in the U.S. reported having rules that prohibited EVP 
use inside their homes (58.6%) and vehicles (63.8%). This is lower than previously reported 
estimates of smoke-free rules in homes (83.7%) and vehicles (78.1%) for combustible 
tobacco products.4 These findings may reflect limited knowledge of the harmful and 
potentially harmful constituents documented in SHA or common EVP marketing strategies, 
some of which have promoted their use in locations where combustible tobacco product 
smoking is prohibited.5
Over 20% of adults reported being unsure of the rules for EVP use inside homes and 
vehicles. Limited knowledge or awareness of EVPs,9,10 varied harm perceptions toward 
SHA exposure,11 limited experience with SHA exposures,8,12 or other factors may have 
contributed to a lack of definitive rules related to EVP use in these environments. Thus, 
these individuals may represent an important segment of the population for targeted 
educational interventions to promote EVP rules in these locations.
Variations in prohibiting EVP use inside homes and vehicles were observed by tobacco 
product use status. Only about 20% of current EVP users, 30% of current cigarette smokers, 
and 40% of other tobacco product users reported not allowing EVP use inside these 
locations. Thus, opportunities exist to educate all tobacco product users about the harms of 
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SHA exposure and the importance of including EVPs in voluntary smoke-free rules in 
private settings.
Approximately one-third of respondents with children either did not prohibit EVP use or 
were unsure of the rules toward EVP use inside their home or vehicle. Secondhand exposure 
to emissions from EVPs and conventional cigarettes can result in similar increases in serum 
cotinine levels among never tobacco users,13 suggesting comparable nicotine exposures 
from SHS and SHA. The U.S. Surgeon General has concluded that nicotine exposure during 
adolescence can harm the developing adolescent brain.5 SHA also can contain other harmful 
constituents that can be particularly problematic for children, including ultrafine particulates, 
which can be inhaled deeply into the lungs. Opportunities exist to educate parents about the 
importance of protecting children from SHA exposure inside homes and vehicles.
Non-Hispanic black respondents and those with lower income and education were less likely 
to report not allowing EVP use inside homes and vehicles, similar to previous findings for 
rules toward combustible tobacco products.4 Furthermore, prohibiting EVP use in these 
locations was less likely among respondents who lived with EVP and other tobacco product 
users. These variations underscore the importance of targeted efforts to educate these 
populations about the harms of SHA exposure, particularly those with the greatest burden of 
exposure.
In recent decades, there has been significant progress in the adoption of smoke-free policies 
in public places.2 However, policies that explicitly address EVP emissions in public places 
are limited. As of December 2017, 9 U.S. states, Washington D.C., Puerto Rico, and about 
500 municipalities have included EVPs in comprehensive smoke-free legislation,14,15 while 
five states prohibit EVP use inside personal vehicles when children are present.16 Although 
the inclusion of EVPs in smoke-free policies is increasing,17 most of the U.S. population 
currently lives in a state where bystanders may be exposed to SHA in public places.15 Thus, 
voluntary smoke-free rules that include EVPs inside homes and vehicles may further protect 
non-users from secondhand emissions to these products. Such rules are particularly 
important for children, who may spend a greater amount of time in these private spaces.18 
Furthermore, voluntary smoke-free rules in these environments that include EVPs could help 
prevent the renormalization of tobacco product use, particularly among youth.5 EVPs and 
SHA can resemble combustible tobacco products and SHS, and youth are particularly 
vulnerable to visual cues and other social norms.5,19
This paper is subject to at least three limitations. First, participants were drawn from an 
Internet-based panel, which may limit generalizability compared to traditional population-
based surveys. Second, the limited sample size prevented the ability to report results 
separately for never and ever EVP users. Finally, a large percentage of respondents reported 
they did not know, or were unsure of, the rules toward EVP use inside their home or vehicle. 
Although respondents who selected this response were maintained for multivariable-adjusted 
analyses, they were considered to have no definitive rule to prohibit the use of EVPs in these 
locations.
Gentzke et al. Page 5
Prev Med. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CONCLUSIONS
In 2017, a majority of adults in the U.S. had voluntary rules prohibiting the use of EVPs 
inside their homes and vehicles. However, variations existed by EVP and other tobacco 
product use. Further, many adults reported being unsure of the rules regarding EVP use in 
these locations. Opportunities exist to educate all adults on the importance of voluntary rules 
that protect non-users from secondhand emissions to all tobacco products, including e-
cigarettes and other electronic vapor products.
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HIGHLIGHTS
• 6 in 10 US adults prohibit electronic vapor product (EVP) use in homes and 
vehicles
• Over 20% of US adults are unsure of the rules toward EVP use in homes and 
vehicles
• Opportunities exist to promote voluntary private smoke-free rules that include 
EVPs
• Smoke-free rules that include EVPs can protect non-users from EVP aerosol 
exposure
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, o
r s
om
e 
ot
he
r e
le
ct
ro
ni
c 
va
po
r 
pr
od
uc
t)”
: (
1) 
“T
he
 ne
x
t f
ew
 q
ue
sti
on
s a
re
 a
bo
ut
 n
ic
ot
in
e.
 H
av
e 
yo
u 
ev
er
 tr
ie
d 
an
y 
of
 th
e 
fo
llo
w
in
g 
pr
od
uc
ts,
 ev
en
 ju
st 
on
e t
im
e?”
 an
d (
2) 
“In
 th
e p
ast
 30
 da
ys,
 w
hic
h o
f th
e f
oll
ow
in
g 
pr
od
uc
ts 
ha
v
e 
yo
u 
u
se
d 
at
 le
as
t o
nc
e?
” 
N
ev
er
 u
se
rs
 r
ep
or
te
d 
ne
v
er
 tr
yi
ng
 E
V
Ps
. T
rie
d,
 n
ot
 c
ur
re
nt
 u
se
rs
 re
po
rte
d 
ev
er
 tr
yi
ng
 E
V
Ps
, b
u
t d
id
 n
ot
 re
po
rt 
us
e 
of
 a
n 
EV
P 
in
 th
e 
pa
st 
30
 d
ay
s. 
Cu
rre
nt
 E
V
P 
us
er
s r
ep
or
te
d 
ev
er
 tr
yi
ng
 
an
 E
V
P,
 
an
d 
re
po
rte
d 
us
in
g 
an
 E
V
P 
at
 le
as
t o
nc
e 
in
 th
e 
pa
st 
30
 d
ay
s.
f C
ur
re
nt
 c
ig
ar
et
te
 s
m
ok
in
g 
sta
tu
s b
as
ed
 o
n 
th
e 
fo
llo
w
in
g 
qu
es
tio
ns
: “
H
av
e 
yo
u 
sm
ok
ed
 a
t l
ea
st 
10
0 
ci
ga
re
tte
s 
in
 y
ou
r e
nt
ire
 li
fe
? 
O
ne
 h
un
dr
ed
 c
ig
ar
et
te
s 
is 
eq
ua
l t
o 
5 
pa
ck
s o
f c
ig
ar
et
te
s.
” 
(Y
es
, 
N
o),
 an
d “
Do
 
yo
u 
no
w
 s
m
o
ke
 c
ig
ar
et
te
s 
ev
er
y 
da
y, 
so
m
e 
da
ys
, o
r n
ot
 a
t a
ll?
” 
N
ev
er
 s
m
o
ke
rs
 r
ep
or
te
d 
th
ey
 h
ad
 n
ot
 sm
ok
ed
 a
t l
ea
st 
10
0 
ci
ga
re
tte
s 
in
 th
ei
r l
ife
tim
e.
 F
o
rm
er
 s
m
o
ke
rs
 r
ep
or
te
d 
th
ey
 h
ad
 sm
ok
ed
 a
t l
ea
st 
10
0 
ci
ga
re
tte
s 
in
 th
ei
r l
ife
tim
e,
 b
u
t c
ur
re
nt
ly
 sm
ok
ed
 c
ig
ar
et
te
s 
“n
ot
 a
t a
ll”
. C
ur
re
nt
 sm
ok
er
s 
re
po
rte
d 
th
ey
 h
ad
 sm
ok
ed
 a
t l
ea
st 
10
0 
ci
ga
re
tte
s 
in
 th
ei
r l
ife
tim
e,
 a
nd
 c
ur
re
nt
ly
 sm
ok
ed
 c
ig
ar
et
te
s 
“e
v
er
y 
da
y”
 o
r 
“
so
m
e 
da
ys
”.
g C
ur
re
nt
 u
se
rs
 o
f o
th
er
 to
ba
cc
o 
pr
od
uc
ts 
re
po
rte
d 
us
e 
of
 th
e 
fo
llo
w
in
g 
to
ba
cc
o 
pr
od
uc
ts 
on
 o
ne
 o
r m
or
e 
of
 th
e 
pa
st 
30
 d
ay
s: 
“C
ig
ar
s 
(bi
g c
iga
rs
, 
ci
ga
ril
lo
s, 
or
 li
ttl
e 
ci
ga
rs
 th
at
 lo
ok
 li
ke
 c
ig
ar
et
te
s)”
, 
“
Sm
ok
el
es
s T
o
ba
cc
o 
(ch
ew
in
g 
to
ba
cc
o,
 sn
uf
f, 
di
p,
 sn
us
, o
r d
iss
ol
va
bl
e 
to
ba
cc
o)”
, “
Pip
es 
fil
le
d 
w
ith
 to
ba
cc
o”
, “
W
at
er
 p
ip
es
, a
lso
 k
no
w
n
 a
s 
ho
ok
ah
s f
ill
ed
 w
ith
 to
ba
cc
o”
, o
r “
So
m
e 
ot
he
r t
ob
ac
co
 p
ro
du
ct
”.
h N
or
th
ea
st:
 C
on
ne
ct
ic
ut
, M
ai
ne
, M
as
sa
ch
us
et
ts,
 N
ew
 H
am
ps
hi
re
, N
ew
 Je
rs
ey
,
 
N
ew
 Y
o
rk
, P
en
ns
yl
va
n
ia
, R
ho
de
 Is
la
nd
, a
nd
 V
er
m
o
n
t. 
M
id
we
st:
 
Ill
in
oi
s, 
In
di
an
a,
 Io
w
a,
 K
an
sa
s, 
M
ic
hi
ga
n
, 
M
in
ne
so
ta
, 
M
iss
ou
ri,
 N
eb
ra
sk
a,
 N
or
th
 D
ak
o
ta
, O
hi
o,
 S
ou
th
 D
ak
o
ta
, a
nd
 W
isc
on
sin
. S
ou
th
: A
la
ba
m
a,
 A
rk
an
sa
s, 
D
el
aw
ar
e,
 D
ist
ric
t o
f C
ol
um
bi
a,
 F
lo
rid
a,
 G
eo
rg
ia
, K
en
tu
ck
y,
 
Lo
ui
sia
na
, M
ar
yl
an
d,
 M
iss
iss
ip
pi
, N
or
th
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Ca
ro
lin
a,
 O
kl
ah
om
a,
 S
ou
th
 C
ar
ol
in
a,
 T
en
n
es
se
e,
 T
ex
as
, 
Vi
rg
in
ia
, a
nd
 W
es
t V
irg
in
ia
. W
es
t: 
A
la
sk
a,
 A
riz
on
a,
 C
al
ifo
rn
ia
, C
ol
or
ad
o,
 H
aw
ai
i, 
Id
ah
o,
 M
on
ta
na
, N
ev
ad
a,
 N
ew
 M
ex
ic
o,
 O
re
go
n,
 U
ta
h,
 
W
as
hi
ng
to
n,
 a
nd
 W
yo
m
in
g.
i B
as
ed
 o
n 
th
e 
qu
es
tio
n,
 “
D
oe
s a
ny
on
e 
w
ho
 li
v
es
 w
ith
 y
ou
 n
ow
 d
o 
an
y 
of
 th
e 
fo
llo
w
in
g?
” 
Re
sp
on
de
nt
s c
ou
ld
 se
le
ct
 o
ne
 o
r m
or
e 
of
 th
e 
fo
llo
w
in
g:
 “
Sm
ok
e 
ci
ga
re
tte
s”
, “
U
se
 e
le
ct
ro
ni
c 
va
po
r p
ro
du
ct
s”
, “
U
se
 
sm
o
ke
le
ss
 to
ba
cc
o 
su
ch
 a
s s
nu
s, 
ch
ew
in
g 
to
ba
cc
o”
, “
Sm
ok
e 
ci
ga
rs
, 
ci
ga
ril
lo
s, 
or
 fi
lte
re
d 
ci
ga
rs
”,
 o
r 
“U
se
 a
ny
 o
th
er
 fo
rm
 o
f t
ob
ac
co
”;
 re
sp
on
de
nt
s c
ou
ld
 a
lte
rn
at
iv
el
y 
se
le
ct
 “
N
o 
on
e 
w
ho
 li
v
es
 w
ith
 m
e 
no
w
 
u
se
s 
an
y 
fo
rm
 o
f t
ob
ac
co
”.
 R
es
po
nd
en
ts 
w
ho
 se
le
ct
ed
 “
U
se
s e
le
ct
ro
ni
c 
va
po
r p
ro
du
ct
s”
 w
er
e 
co
ns
id
er
ed
 a
s l
iv
in
g 
w
ith
 a
n 
EV
P 
us
er
.
 
R
es
po
nd
en
ts 
w
ho
 se
le
ct
ed
 o
ne
 o
r m
or
e 
of
 re
sp
on
se
s f
or
 c
ig
ar
et
te
s,
 
sm
o
ke
le
ss
 to
ba
cc
o,
 c
ig
ar
s,
 o
r 
o
th
er
 fo
rm
s o
f t
ob
ac
co
 w
er
e 
co
ns
id
er
ed
 a
s l
iv
in
g 
w
ith
 o
th
er
 to
ba
cc
o 
pr
od
uc
t u
se
rs
.
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Table 2
Socio-demographic and tobacco use correlates a of prohibiting the use of electronic vapor products inside 
homes and vehicles among adults, Summer Styles Survey – United States, 2017
Overall Sample b Home c Vehicle d
n (%) aPR (95% CI) aPR (95% CI)
Sex
Male 2,004 (48.2) ref ref
Female 2,103 (51.8) 1.00 (0.95–1.05) 0.98 (0.93–1.03)
Age
18–24 261 (12.0) ref ref
25–44 1,350 (34.1) 0.84 (0.76–0.94) 0.94 (0.85–1.05)
45–64 1,724 (34.3) 0.91 (0.82–1.00) 1.00 (0.91–1.10)
65+ 772 (19.5) 0.95 (0.85–1.05) 1.05 (0.95–1.17)
Race
White, Non-Hispanic 3,004 (64.4) ref ref
Black, Non-Hispanic 369 (11.8) 0.85 (0.76–0.95) 0.89 (0.82–0.98)
Hispanic 497 (15.7) 0.94 (0.86–1.03) 0.93 (0.86–1.01)
Other, Non-Hispanic 237 (8.0) 1.05 (0.94–1.18) 0.99 (0.89–1.10)
Education
<High School 257 (11.6) ref ref
High School 1,269 (29.0) 1.06 (0.93–1.20) 1.05 (0.94–1.17)
Some College 1,228 (28.6) 1.12 (0.98–1.28) 1.09 (0.97–1.23)
College Degree 1,326 (30.8) 1.27 (1.11–1.45) 1.16 (1.03–1.31)
Respondent has Child <18 years
No 2,742 (72.7) ref ref
Yes 1,346 (37.3) 1.15 (1.09–1.22) 1.12 (1.07–1.18)
Current EVP use Status e
Never user 3,481 (85.0) ref ref
Tried, not current user 463 (11.8) 0.77 (0.68–0.86) 0.78 (0.70–0.86)
Current User 123 (3.3) 0.66 (0.48–0.90) 0.59 (0.43–0.81)
Current Smoking Status f
Never Smoker 2,339 (60.4) ref ref
Former Smoker 1,093 (25.9) 0.92 (0.86–0.98) 0.92 (0.86–0.97)
Current Smoker 529 (13.7) 0.73 (0.64–0.83) 0.68 (0.60–0.77)
Other Tobacco Product Use g
Non-current User 3,889 (95.9) ref ref
Current User 170 (4.1) 0.90 (0.78–1.04) 0.85 (0.74–0.97)
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Overall Sample b Home c Vehicle d
n (%) aPR (95% CI) aPR (95% CI)
U.S. Census Region h
Northeast 792 (18.0) ref ref
Midwest 893 (21.0) 1.00 (0.92–1.09) 1.05 (0.97–1.13)
South 1,496 (37.4) 1.01 (0.94–1.09) 1.03 (0.96–1.11)
West 926 (23.5) 1.07 (0.99–1.16) 1.10 (1.02–1.19)
Annual Household Income
<$15,000 208 (7.9) ref ref
$15,000–$24,999 206 (8.0) 1.23 (0.98–1.55) 1.18 (0.98–1.42)
$25,000–$39,999 614 (12.8) 1.38 (1.12–1.70) 1.23 (1.04–1.46)
$40,000–$59,999 678 (15.0) 1.27 (1.03–1.56) 1.16 (0.98–1.37)
≥$60,000 2,401 (56.2) 1.39 (1.14–1.70) 1.23 (1.05–1.45)
Lives with EVP user i
No 3,877 (95.1) ref ref
Yes 195 (4.9) 0.68 (0.55–0.84) 0.71 (0.59–0.86)
Lives with other tobacco product user i
No 3,098 (80.6) ref ref
Yes 713 (19.4) 0.87 (0.80–0.95) 0.84 (0.77–0.91)
Abbreviations: aPR= Adjusted Prevalence Ratio CI = Confidence Interval; EVP = Electronic Vapor Product
a
aPRs were calculated as model-adjusted risk ratios using binary logistic regression modeling with predictive margins. All covariates were entered 
into the model simultaneously. Associations between levels of each covariate and prohibiting EVP use are compared to each specified referent 
group.
bOverall sample size: n based on unweighted data; % based on weighted data. Data were weighted to Current Population Survey distributions. n’s 
may not add up to the total sample size (n=4,107) due to missing data; %’s may not add up to 100% due to rounding.
c
Based on the question: “Which statement best describes the rules about using electronic vapor products inside your home?” Responses were 
dichotomized as “not allowed” (It is not allowed anywhere or at any time inside my home”) or “allowed” (“It is allowed in some places or at some 
times inside my home”, “It is allowed anywhere and at any time inside my home”, or “Don’t Know, Not Sure”).
d
Based on the question: “Regardless of whether you use them, which statement best describes the rules about using electronic vapor products 
inside vehicles that you or your family members who live with you own or lease?” Responses were dichotomized as “not allowed” (“It is not 
allowed anywhere or at any time inside any vehicle”) or “allowed” (“It is allowed inside certain vehicles or during certain times”, “It is allowed 
anywhere and ay any time inside any vehicle”, or “Don’t Know, Not Sure”). An additional response, “My family and I do not lease or own any 
vehicles” was excluded from the analysis.
eCurrent EVP use status based on the following questions regarding “Electronic vapor products (e.g., e-cigarettes, e-hookahs, e-cigars, e-pipes, 
hookah pens, vape pens, or some other electronic vapor product)”: (1) “The next few questions are about nicotine. Have you ever tried any of the 
following products, even just one time?” and (2) “In the past 30 days, which of the following products have you used at least once?” Never users 
reported never trying EVPs. Tried, not current users reported ever trying EVPs, but did not report use of an EVP in the past 30 days. Current EVP 
users reported ever trying an EVP, and reported using an EVP at least once in the past 30 days.
fCurrent cigarette smoking status based on the following questions: “Have you smoked at least 100 cigarettes in your entire life? One hundred 
cigarettes is equal to 5 packs of cigarettes.” (Yes, No), and “Do you now smoke cigarettes every day, some days, or not at all?” Never smokers 
reported they had not smoked at least 100 cigarettes in their lifetime. Former smokers reported they had smoked at least 100 cigarettes in their 
lifetime, but currently smoked cigarettes “not at all”. Current smokers reported they had smoked at least 100 cigarettes in their lifetime, and 
currently smoked cigarettes “every day” or “some days”.
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gCurrent users of other tobacco products reported use of the following tobacco products on one or more of the past 30 days: “Cigars (big cigars, 
cigarillos, or little cigars that look like cigarettes)”, “Smokeless Tobacco (chewing tobacco, snuff, dip, snus, or dissolvable tobacco)”, “Pipes filled 
with tobacco”, “Water pipes, also known as hookahs filled with tobacco”, or “Some other tobacco product”.
hNortheast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: 
Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, 
Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South 
Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New 
Mexico, Oregon, Utah, Washington, and Wyoming.
i
Based on the question, “Does anyone who lives with you now do any of the following?” Respondents could select one or more of the following: 
“Smoke cigarettes”, “Use electronic vapor products”, “Use smokeless tobacco such as snus, chewing tobacco”, “Smoke cigars, cigarillos, or filtered 
cigars”, or “Use any other form of tobacco”; respondents could alternatively select “No one who lives with me now uses any form of tobacco”. 
Respondents who selected “Uses electronic vapor products” were considered as living with an EVP user. Respondents who selected one or more of 
responses for cigarettes, smokeless tobacco, cigars, or other forms of tobacco were considered as living with other tobacco product users.
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